Use of Cannabidiol in the Treatment of Epilepsy: Efficacy and Security in Clinical Trials

Silvestro, Serena; Mammana, Santa; Cavalli, Eugenio; Bramantı, Placido; Mazzon, Emanuela

doi:10.3390/molecules24081459

Cited by 161 publications

(131 citation statements)

References 88 publications

Supporting

Mentioning

124

Contrasting

Unclassified

Order By: Relevance

“…CBD functions as a negative allosteric modulator of CB 1 receptor (51). Therefore, it has therapeutic potential in the treatment of the central nervous system diseases (neurodegenerative diseases, epilepsy, anxiety, and depression) without concurrent psychotic side effects (2,52,53). Furthermore, it was indicated that CBD is able to block CB 1 receptor, thereby producing anti-obesity effects.…”

Section: Cannabidiol (Cbd)mentioning

confidence: 99%

“…Currently, the first cannabis based medicine containing CBD/ 9 -THC combination for the multiple sclerosis related spasticity treatment (Sativex/Nabiximols; GW Pharmaceuticals) has been approved in numerous countries, including Australia, Canada, New Zealand and in most European Union countries (72). Furthermore, a drug composed solely of CBD (Epidiolex; GW Pharmaceuticals) has been approved in June 2018 in the United States for the treatment of Dravet and Lennox-Gastaut syndromes in children (52,73,74).…”

Section: Cannabidiol (Cbd)mentioning

confidence: 99%

See 1 more Smart Citation

Phytocannabinoids: Useful Drugs for the Treatment of Obesity? Special Focus on Cannabidiol

2020

View full text Add to dashboard Cite

Currently, an increasing number of diseases related to insulin resistance and obesity is an alarming problem worldwide. It is well-known that the above states can lead to the development of type 2 diabetes, hypertension, and cardiovascular diseases. An excessive amount of triacylglycerols (TAGs) in a diet also evokes adipocyte hyperplasia and subsequent accumulation of lipids in peripheral organs (liver, cardiac muscle). Therefore, new therapeutic methods are constantly sought for the prevention, treatment and alleviation of symptoms of the above mentioned diseases. Currently, much attention is paid to Cannabis derivatives-phytocannabinoids, which interact with the endocannabinoid system (ECS) constituents. 9-tetrahydrocannabinol (9-THC) and cannabidiol (CBD) are the most abundant compounds of Cannabis plants and their therapeutic application has been suggested. CBD is considered as a potential therapeutic agent due to its anti-inflammatory, anti-oxidant, anti-tumor, neuroprotective, and potential anti-obesity properties. Therefore, in this review, we especially highlight pharmacological properties of CBD as well as its impact on obesity in different tissues.

show abstract

Section: Cannabidiol (Cbd)mentioning

confidence: 99%

Section: Cannabidiol (Cbd)mentioning

confidence: 99%

Phytocannabinoids: Useful Drugs for the Treatment of Obesity? Special Focus on Cannabidiol

2020

View full text Add to dashboard Cite

show abstract

“…The other indication awarded to GW was specific to DS, which a similar series of clinical trials were performed following preclinical research suggesting potential seizure reduction through its agonistic action on the CB1 and CB2 receptors (Anwar et al, 2019;Silvestro et al, 2019). The same titration method, dosage, and time of use was used to evaluate the safety and efficacy on patients suffering from DS; however, this study contained a smaller participant pool of 61 patients receiving the drug and 59 receiving the placebo.…”

Section: Epileptic Seizuresmentioning

confidence: 99%

Cannabidiol Drugs Clinical Trial Outcomes and Adverse Effects

et al. 2020

View full text Add to dashboard Cite

This review aims to present completed clinical trial data surrounding the medicinal benefits and potential side effects of the increasingly popular cannabidiol (CBD)-based drug products, specifically Epidiolex. The article is divided into two sections based on if the ailment being treated by this cannabinoid is classified as either physiological or neurological conditions. In addition to describing the current status, we also examined the different primary and secondary outcomes recorded for each study, which varies greatly depending on the funding source of the clinical trial. With the recent FDA-approval of Epidiolex, this review mainly focused on trials involving this specific formulation since it is the only CBD-based drug currently available to clinicians, although all other clinically trialed CBD(A) drugs were also examined. We hope this review will help guide future research and clinical trials by providing the various outcomes measured in a single review.

show abstract

“…Regarding oxidative stress, some of the current treatments could already be addressing this problem. In addition to DS, cannabidiol (CBD) is being used or in clinical trials for several types of epilepsy [194], and it has a neuroprotective effect by inhibiting nitric oxide production, one of the main neurotoxic effectors [195]. The ketogenic diet, high in fats and low in carbohydrates and proteins, is also widely used to treat refractory epilepsies [196].…”

Section: Oxidative Stress and Neuroinflammation As Therapeutic Targetmentioning

confidence: 99%

Oxidative Stress, a Crossroad Between Rare Diseases and Neurodegeneration

et al. 2020

View full text Add to dashboard Cite

Oxidative stress is an imbalance between production and accumulation of oxygen reactive species and/or reactive nitrogen species in cells and tissues, and the capacity of detoxifying these products, using enzymatic and non-enzymatic components, such as glutathione. Oxidative stress plays roles in several pathological processes in the nervous system, such as neurotoxicity, neuroinflammation, ischemic stroke, and neurodegeneration. The concepts of oxidative stress and rare diseases were formulated in the eighties, and since then, the link between them has not stopped growing. The present review aims to expand knowledge in the pathological processes associated with oxidative stress underlying some groups of rare diseases: Friedreich's ataxia, diseases with neurodegeneration with brain iron accumulation, Charcot-Marie-Tooth as an example of rare neuromuscular disorders, inherited retinal dystrophies, progressive myoclonus epilepsies, and pediatric drug-resistant epilepsies. Despite the discrimination between cause and effect may not be easy on many occasions, all these conditions are Mendelian rare diseases that share oxidative stress as a common factor, and this may represent a potential target for therapies.

show abstract

Use of Cannabidiol in the Treatment of Epilepsy: Efficacy and Security in Clinical Trials

Cited by 161 publications

References 88 publications

Phytocannabinoids: Useful Drugs for the Treatment of Obesity? Special Focus on Cannabidiol

Phytocannabinoids: Useful Drugs for the Treatment of Obesity? Special Focus on Cannabidiol

Cannabidiol Drugs Clinical Trial Outcomes and Adverse Effects

Oxidative Stress, a Crossroad Between Rare Diseases and Neurodegeneration

Contact Info

Product

Resources

About